Physician profile
Hansel Noffsinger
NPI 1801802863
$1,339.08
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $234 · 2021: $358 · 2022: $357 · 2023: $159 · 2024: $35.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $290.75 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $161.58 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $95.79 | 2020-2021 | |
| Abbott Laboratories | $95.62 | 2022 | |
| Amarin Pharma, INC. | $90.97 | 2020-2021 | |
| Novo Nordisk INC | $85.48 | 2020-2024 | Wegovy |
| Abbvie INC. | $81.51 | 2023 | |
| Pfizer INC. | $73.84 | 2019-2022 | |
| Grifols USA, LLC | $48.41 | 2021 | |
| Astellas Pharma US INC | $33.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.13 | 2019-2022 | |
| Medtronic, INC. | $30.05 | 2021 | |
| Ibsa Pharma INC. | $22.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.87 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.44 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.14 | 2021 | |
| Mylan Specialty L.P. | $15.25 | 2021 | |
| Adlon Therapeutics L.P. | $13.74 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.55 | 2019 | |
| Shire North American Group INC | $13.25 | 2019 | |
| Currax Pharmaceuticals LLC | $12.61 | 2021 | |
| Opko Pharmaceuticals, LLC | $12.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.65 | 2022 | |
| Allergan, INC. | $11.59 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hansel Noffsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.